Achieve Life Sciences (ACHV) Competitors $2.71 +0.07 (+2.65%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACHV vs. VNDA, VSTM, CDXS, AGEN, IRWD, SGMO, DOMH, FBIO, CRIS, and SABSShould you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Codexis (CDXS), Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Dominari (DOMH), Fortress Biotech (FBIO), Curis (CRIS), and SAB Biotherapeutics (SABS). These companies are all part of the "biotechnology" industry. Achieve Life Sciences vs. Its Competitors Vanda Pharmaceuticals Verastem Codexis Agenus Ironwood Pharmaceuticals Sangamo Therapeutics Dominari Fortress Biotech Curis SAB Biotherapeutics Vanda Pharmaceuticals (NASDAQ:VNDA) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings. Which has more risk and volatility, VNDA or ACHV? Vanda Pharmaceuticals has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Do institutionals & insiders believe in VNDA or ACHV? 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 8.9% of Vanda Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is VNDA or ACHV more profitable? Achieve Life Sciences has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -21.98%. Vanda Pharmaceuticals' return on equity of -8.30% beat Achieve Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Vanda Pharmaceuticals-21.98% -8.30% -6.85% Achieve Life Sciences N/A -176.11%-103.32% Do analysts recommend VNDA or ACHV? Vanda Pharmaceuticals presently has a consensus target price of $16.50, indicating a potential upside of 241.90%. Achieve Life Sciences has a consensus target price of $14.33, indicating a potential upside of 428.91%. Given Achieve Life Sciences' higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Vanda Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Does the media refer more to VNDA or ACHV? In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 1 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 1.04 beat Vanda Pharmaceuticals' score of 0.63 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Vanda Pharmaceuticals Positive Achieve Life Sciences Positive Which has stronger valuation & earnings, VNDA or ACHV? Vanda Pharmaceuticals has higher revenue and earnings than Achieve Life Sciences. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVanda Pharmaceuticals$198.77M1.43-$18.90M-$0.75-6.43Achieve Life SciencesN/AN/A-$39.83M-$1.34-2.02 SummaryVanda Pharmaceuticals beats Achieve Life Sciences on 8 of the 15 factors compared between the two stocks. Get Achieve Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHV vs. The Competition Export to ExcelMetricAchieve Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.01M$2.44B$5.56B$9.30BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-2.029.1628.6119.64Price / SalesN/A735.94437.49188.30Price / CashN/A164.3436.0257.93Price / Book4.444.688.185.63Net Income-$39.83M$30.99M$3.23B$257.73M7 Day Performance14.35%0.57%-0.25%0.07%1 Month Performance-12.58%7.91%5.40%8.32%1 Year Performance-44.12%-5.94%26.35%13.78% Achieve Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHVAchieve Life Sciences2.8276 of 5 stars$2.71+2.7%$14.33+428.9%-46.7%$94.01MN/A-2.0220Positive NewsVNDAVanda Pharmaceuticals4.6922 of 5 stars$4.89-1.6%$16.50+237.4%-20.9%$292.90M$198.77M-6.52290VSTMVerastem3.0776 of 5 stars$4.69-2.3%$13.38+185.2%+45.1%$263.76M$10K-1.4750CDXSCodexis3.4518 of 5 stars$2.58-6.9%$11.00+326.4%-14.1%$229.48M$59.35M-2.61250Positive NewsAGENAgenus4.2259 of 5 stars$5.18-14.7%$14.00+170.3%-60.1%$166.42M$103.46M-0.60440High Trading VolumeIRWDIronwood Pharmaceuticals4.3492 of 5 stars$0.71-6.9%$4.78+570.9%-89.4%$123.95M$351.41M-3.56220Positive NewsSGMOSangamo Therapeutics2.689 of 5 stars$0.51-2.9%$4.50+779.2%+11.7%$122.86M$57.80M-1.31480Positive NewsDOMHDominari1.0989 of 5 stars$5.10-3.2%N/A+180.6%$77.17M$18.15M-1.134News CoveragePositive NewsFBIOFortress Biotech2.5195 of 5 stars$1.91+1.6%$21.00+999.5%-3.0%$55.59M$57.67M-0.86170Positive NewsCRISCuris2.5594 of 5 stars$1.74-3.9%$17.00+877.0%-73.6%$18.94M$10.91M-0.2860Positive NewsHigh Trading VolumeSABSSAB Biotherapeutics3.1745 of 5 stars$1.96+14.0%$13.25+576.0%-12.4%$15.98M$1.32M0.00140Gap Up Related Companies and Tools Related Companies VNDA Alternatives VSTM Alternatives CDXS Alternatives AGEN Alternatives IRWD Alternatives SGMO Alternatives DOMH Alternatives FBIO Alternatives CRIS Alternatives SABS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACHV) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Next Commodity Crisis Just Got a Name: SilverElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
